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Abstract 
 
DAVID A. DETWILER: Isolation of Primary Canine Satellite Cells  
(Under the direction of Joe N. Kornegay D.V.M. – Ph.D.  
and Nancy L. Allbritton M.D. – Ph.D.) 
 
Duchenne muscular dystrophy (DMD) is a debilitating disease that principally affects 
striated muscles (skeletal and cardiac) and is the most severe form of muscular dystrophy.  
Disruption of the dystrophin gene is the primary cause of disease leading to excessive 
muscle damage.  Regenerative processes counterbalance damage but individuals with 
DMD eventually succumb to immobilizing loss of strength and death from cardiac and 
pulmonary complications in their late teens and twenties.  Golden retriever muscular 
dystrophy (GRMD) is a large animal model with better mimicry of the human disease 
than mouse models.  Its development and characterization are critical to developing 
therapies for DMD.  The cells primarily responsible for the regenerative response in 
skeletal muscle are satellite cells.  These cells have been characterized at the protein level 
previously with only minor differences found between normal and dystrophic cultures.  
However, satellite cells have not been characterized at the transcriptional level. Pax7, 
MyoD, Myogenin and Utrophin act as critical members in the path to myogenesis.  In this 
work, we have looked at the mRNA variation in cells collected from normal and GRMD 
animals and found substantial differences in mRNA expression profiles.  These finding 
are also reflected in cell fusion experiments done on the same cultures.  Studying these 
proteins and mRNAs in vitro under growth and differentiating conditions can help 
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characterize satellite cells in the GRMD model. To sort through the heterogeneity of 
satellite cell populations, clonal cultures are needed to better characterize protein and 
mRNA patterns in these cells.  Methods such as limiting dilution or flow cytometry 
require considerable time and resources to clone and verify large numbers of colonies for 
analysis. Micropallet array technology is a cell sorting method that permits clonal culture 
of large numbers of cells in very small spaces. Employing its flexible nature, micropallet 
array technology has been adapted to culture primary satellite cells from the GRMD 
model.  Using these adaptations, clonal colonies have been cultured and shown to 
proliferate on tri-partite micropallet arrays.  This forms two sister colonies where one 
sister colony can be analyzed and the other reserved for continued culture and 
downstream experiments.  
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Chapter 1 
Introduction 
Background and Significance 
Muscular dystrophy is a spectrum of diseases that affects principally striated 
(skeletal and cardiac) muscles [1-5]. The most severe form of muscular dystrophy, 
Duchenne Muscular Dystrophy (DMD), presents a progressive loss of strength in the 
skeletal muscles and leads to muscle atrophy. Complications from progressive muscle 
deterioration limit the lifespan of affected individuals to two to three decades. Several 
animal models for DMD have been developed, with the two most important being the 
mouse (MDX – Muscular Dystrophy X-Linked) and the canine (GRMD - Golden 
Retriever Muscular Dystrophy). The mouse model has been used extensively to examine 
the underlying disease physiology [6, 7]. The canine model, GRMD, better mimics the 
human disease in severity and is a size relevant model [8, 9]. Currently there are no 
clinically available therapies that correct or halt the progression of the disease, though 
clinical trials are underway [10-12].    
Genetics and Occurrence 
Duchenne Muscular Dystrophy is a genetic disease primarily related to the 
functions of the dystrophin gene and affects the skeletal muscles [10-12].  The gene is 
encoded on the X-chromosome, Xp21, and subsequently primarily occurs in males [1, 
13].  DMD affects one in 3500 to 7500 males [14].  Many cases of DMD are inherited. 
However, due to the large size of the dystrophin gene, 2.4 megabases in length, 
spontaneous mutations are a common occurrence [13, 15, 16].  These can be small point 
mutations or deletions that can create a stop codon or change the reading frame to large 
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deletions.  Either way, a truncated, poorly functioning or non-existent dystrophin protein 
results.  
Dystrophin Function 
Dystrophin is found in many tissue types outside of skeletal muscle including 
neural, smooth muscle and cardiac tissues, though transcriptional variants may be found 
in these tissues [17].  Its primary role is that of mediating force transduction from the 
actin-myosin network in the skeletal muscle to the laminin and collagen extracellular 
matrix surrounding the muscle fibers that come together to form tendons [18]. However, 
dystrophin does not do this alone.  It is a major part of the dystrophin glycoprotein 
complex (DGC) [18].  Without dystrophin this complex does not form and forces are 
unevenly transmitted through the cell membrane of the muscle cells, the sarcolemma, 
causing tears in the membrane. Tears allow extracellular calcium to enter the cells 
causing the fiber to undergo necrosis [19, 20].  Utrophin is the autosomal homologue of 
dystrophin and is up-regulated in DMD.  Though genetically homologous, it can’t fully 
replace the functions of dystrophin and organize the formation of the DGC [21, 22]. 
Clinical Diagnosis and Disease Progression 
DMD is diagnosed in early childhood due to a lagging in physical development 
and a loss of strength.  Without any viable clinical therapies, boys have a progressive loss 
in strength and are often confined to a wheelchair early in their second decade of life.  
The weakened state of the muscles is due to a lack of capacity to deal with forces coming 
into and generated by the muscles.  This damages the muscle fibers and leads to a 
regenerative cycle to rebuild the muscle.  This cycle of damage and repair continues for 
years leading to identifiable histological pathologies, including most notably individual 
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and grouped muscle fiber necrosis.  There are increases in the amount of fibrous 
connective tissue and fat within the body of the muscle [23, 24].  Muscle fibers are 
variably sized, ranging from small ones undergoing regeneration to others that are 
markedly enlarged due to hypertrophy.  DMD patients suffer from cardiac and breathing 
problems as their heart and diaphragm begin to fail, causing many patients die in their 
late teens to twenties. 
Animal Models  
DMD has been identified in numerous vertebrates. However, only a few models 
of DMD have been characterized in mice, cats, and dogs [8, 9]. Many studies have been 
completed in mdx mice, because of the ease of keeping a colony, the short breeding time, 
and the ability to do many replicates. Much of our molecular understanding of DMD has 
come from the study of the mdx mouse [6, 7]. The mdx mouse remains relatively normal 
clinically, but in contrast, dystrophin-deficient dogs develop progressive disease similar to 
the human condition [8, 9].  The most commonly studied canine model is golden retriever 
muscular dystrophy (GRMD).  GRMD is characterized by a point mutation between the 
sixth and seventh exon of the dystrophin mRNA that causes the seventh exon to be 
excluded from the nascent mRNA [25].  This leads to a reading frame shift and the 
formation of an early stop codon, resulting in a truncated non-functional protein.  
However, some cells can create alternate combinations of the exons and translate 
truncated but functional protein, resulting in relatively normal muscle fibers, termed 
revertant fibers [1, 26].  Another canine model, the German short haired pointer (GSHP), 
has a large genetic deletion, essentially amounting to a dystrophin knock-out [27].   These 
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GSHP dogs do not have revertant fibers, thus facilitating studies to define the immune 
response with forms of genetic therapy that restore dystrophin. 
Therapies 
There are no viable therapies for DMD that exist as a standard of care, although 
research has led to clinical trials on several fronts.  Therapies fall into three basic 
categories with hybrid combinations.  The first therapeutic approach is pharmaceutical.  
A long used drug in the form of the corticosteroid, prednisone, can reduce some of the 
symptoms of DMD, thus, for instance, delaying the time at which affected boys must 
transition to wheelchairs [28, 29].  Other drugs target stop codon read-through and exon 
skipping to get around point mutations that cause an early termination of the protein [30].  
Some of these drugs are in clinical trials. 
Another major means of therapy is to manipulate the genetics of the individual.  
This can be achieved through systemic delivery of DNA or RNA based vectors that are 
capable of introducing a gene or RNA transcript that can replace the dysfunctional 
dystrophin gene or modify the mRNA that the nucleus produces.  These methods have 
met with some substantial success in restoring dystrophin production and reestablishing 
the DGC at the sarcolemma [22].  Viruses can also be used to introduce a modified gene 
or RNA.  Two common categories of viruses that are used to introduce a gene are adeno-
associated viruses (AAV) and retroviruses.  Regardless of the vector, the gene that is 
delivered is restricted in size by the packaging capacity of the virus [31, 32].  Viral 
therapy has had some success in integrating recombinant genes into dystrophic mice and 
dogs [10, 32, 33].  
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Cell based therapies have been developed for two main reasons.  The first is due 
to the success of bone marrow transplantation in curing a number of diseases. This has 
served as the paradigm for cell transplantation.  The second is that cell transplantation 
could potentially restore some or all of the muscle mass associated with muscle atrophy 
as the individual ages. There are two potential sources for cells.  Allogeneic cells can be 
collected from donors, immunologically matched and transplanted into the recipient.  
Allogeneic cells provide the opportunity to restore native dystrophin to the muscles with 
all of the molecular regulation in place, assuming a normal donor. Alternatively, 
autologous transplantation involves the collection of a stem cell population from the 
patients and then modifying the cells to replace or restructure the dysfunctional 
dystrophin. 
Several types of cells have been used in DMD studies.  The first type is myoblasts 
and their stem cell, the satellite cell. Satellite cells occupy an anatomical niche between 
the sarcolemma of the myofiber and the basement membrane. This position is what 
allowed satellite cells to be first identified in 1961 by Katz and Mauro. Satellite cells 
remain quiescent when there is no need for muscle repair and then activate quickly to 
provide numerous myoblasts to repair damage. Furthermore, they are able to self-renew 
to maintain the number of satellite cells [34]. 
Myoblast transfer therapy was shown, by Partridge et al, to be a viable in-vivo, 
cell-based therapy [35]. Studies using the mdx mouse showed that myoblasts could be 
successfully delivered to muscles and that they could then fuse with the host myofibers 
and contribute proteins [36, 37]. This led to human clinical trials in the 1990’s [38].  
Though allogeneic transplantation has been shown to be successful in mice, similar 
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transplants in dogs and humans have met with limited success due to failure to produce 
functional gains in strength or mitigate disease progression [39, 40].  Immune rejection 
and limited cell survival may have restricted the success of these studies [3, 39].  Satellite 
cells remain of great interest as they are the natural stem cell involved with muscle 
regeneration and are readily available from simple biopsies.  
Besides the satellite cells and associated myoblasts, there are many adult stem cell 
populations throughout the body capable of multi-lineage differentiation [41-44].  Bone 
marrow has two sets of cells that have been tested for contribution to muscle 
regeneration.  Both are readily obtainable during the entire lifetime of a DMD patient or 
GRMD dog.  The first are bone marrow stromal cells (MSCs). These mesodermal cells 
line bone trabeculae.  Stromal cells injected directly into the muscle, without a forced 
differentiation toward myogenic lineage, contribute very little to muscle regeneration in 
mouse models [45, 46].  The second set of bone marrow cells contributing to muscle 
regeneration are the hematopoietic stem cells.  Dell’Agnola et al used the GRMD model, 
termed CXMD in their studies, to determine the contribution of an allogeneic bone 
marrow transplant to regenerating muscle [47]. Despite successful allogeneic 
engraftment, bone marrow-derived cells did not contribute either skeletal muscle or 
muscle precursor cells.   
More recently, vascular associated stem cells, called mesoangioblasts, have been 
used to contribute to muscle regeneration [48-52]. These cells are multipotent, with 
capacity to give rise to osteogenic, adipogenic, myogenic, and endothelial lineages. The 
initial work was done in embryos of chick, quail, and mouse and was then taken to the 
canine model [51, 52]. This study showed that clinically-relevant cell mass can be 
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obtained for transplant into GRMD dogs.  A variety of surface markers, including c-met, 
M-cadherin, VE-cadherin, P-selectin, and VEGF-receptor 2 but not CD34, CD45 or 
CD31, have been identified on these cells [52]. Mesoangioblasts can be injected directly 
into the muscle or intra-arterially. Polyclonal populations of cells were injected in the 
femoral artery so as to allow cells direct access to the downstream capillary beds [52]. 
Outcomes varied from normal disease progression to an almost normal histological 
phenotype.  However, questions have been raised about the outcome parameters used and 
the role that immunosuppression may have played in improvement [53]. 
Characterization of cell types 
 With the use of cellular therapies, there is a need to understand the exact nature of 
the cells being used.  Transplanted bone marrow will repopulate an irradiated animal.  
Characterization of the cell populations within the biopsy is critical to limit potential side 
effects, treat the disease with a greater degree of precision, and better understand the 
fundamental biology of the stem cell.  The same is true for cell populations used in 
myogenic therapy. Cell size, shape, proliferation rate and protein expression are all 
important in the characterization of a particular population.  Satellite cells and myoblasts 
have been characterized from mouse, human and dog [34, 54-57].  These studies have 
focused on the protein expression of cells, either intracellular where 
immunohistochemistry is used or vital cell techniques, such as flow cytometry, where 
cells can be characterized and subsequently used in downstream experiments. Antibody 
resources for mouse models and humans have been well developed but resources for dogs 
lack the same level of diversity and availability. 
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The myogenic potential of cells has also been characterized in vitro [55, 57].  This 
involves differentiating the cells down the myogenic pathway towards the production of 
multinucleated myotubes in cell fusion experiments. Quantitation of the number of cell 
fusions and the number of nuclei per myotube are used to demonstrate the ability of cells 
to contribute to muscle regeneration in vivo.  Though useful in demonstrating the ability 
of cells to differentiate, it is not a measure of the success that a cell will have after being 
transplanted into the body.  A number of differences have been characterized in cells 
derived from different species, mostly in regard to surface antigens used in flow 
cytometry.  
Micropallet arrays 
Micropallet arrays are a new tool that can be used to sort adherent cells [58-60].  
They are fabricated using a photolithography technique and a light sensitive 
polymerization reaction of a photoresist [58].  A mask permits UV light to pass through 
and cause a photoinitiator to crosslink monomers into a solid form, Figure 1.1A. 
Unpolymerized material is dissolved away revealing the pattern of individual structures, 
termed micropallets.  This array is then treated with a chemical that creates a 
hydrophobic layer.  When aqueous solutions such as culture media are applied, virtual air 
Figure 1.1. Micropallet arrays. A) Scanning Electron Microscopy of micropallet array with HeLa 
cells.  Array dimensions are 50 × 50 µm (L × W).  B) Schematic of a side view of a functional 
micropallet array. 
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walls are created between the micropallets.  This permits cells seeded onto the array to 
only interact with the top surface of the micropallets Figure 1.1B.  Individual 
micropallets, which contain cells, can then be released from the surface with the aid of a 
focused laser pulse and collected for further culture or analysis [61]. 
Micropallet arrays provide a means to clonally culture and isolate cells based on a 
wide range of characteristics [58, 62, 63].  These include the presence or absence of 
fluorescently tagged proteins and additional criteria not available to flow cytometry 
including their adherent morphology, growth rate, and other dynamic behavior [58, 60]. 
With the large number of pallets available on an array, the cloning and isolation of 
moderate to large numbers of cells is greatly simplified over standard tissue culture 
cloning techniques. Micropallet arrays have previously been used to clone and sort tumor 
cells, murine embryonic stem cells, and other cell lines [58, 60, 62]. While cell lines have 
been adapted to cell culture conditions for numerous generations, more physiologically 
relevant primary cells are not so adept at adhesion to artificial surfaces. A tailored culture 
environment is required to meet the needs of these primary cells.  
 The 1002F photoresist from which the micropallet arrays are fabricated has been 
shown to be suitable for culturing tumor cell lines [58, 60, 62, 63]. In some instances the 
1002F required an additional coating such as collagen or fibronectin for cell attachment 
and growth.  An alternative means of applying a protein or other material to the surface 
of an array is contact printing [64].  This process involves spreading a thin layer of 
dissolved protein or other material on a standard glass slide.  The micropallet array is 
then inverted and briefly pressed into contact with the coated slide.  The array is removed 
from the slide and now contains a thin layer of material on the surface of the 
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micropallets.  Cells can then be cultured on this alternative surface.  This means the 
micropallet technology can be adapted and optimized to a variety of cell types including 
stem cells. 
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Chapter 2 
Isolation, Culture, and Characterization of Primary Canine  
Satellite Cells from the GRMD Model 
 
Introduction 
Duchenne Muscular Dystrophy (DMD) is an inherited, progressive 
neuromuscular disease caused by mutations in the dystrophin gene and is characterized 
by ongoing cycles of degeneration and regeneration leading to progressive loss of muscle 
strength.  No treatment has been shown to halt progression of the disease, although gene, 
cell, and pharmacologic approaches have been studied.  Cell based therapies, whereby 
normal or genetically-corrected autologous cells are expanded in culture and transplanted 
into dystrophic individuals, in principle, offer the advantage of actually restoring muscle 
mass. Satellite cells, myoblasts, and other myogenic stem cells are the most promising 
candidates for transplantation.  
 Despite promising results in the dystrophin-deficient mdx mouse, myoblast 
transplantation was largely ineffective in DMD patients due to the combined deleterious 
effects of early cell death, immune rejection, and poor migration beyond the transplant 
site [2, 5, 39].  The use of earlier muscle progenitor cells circumvents these issues to 
some extent, in that stem cells have a greater capacity to replicate, are less prone to 
immune rejection, and can potentially “home” to muscle [4, 52, 65-67]. 
 Over the past 25 years, extensive studies have been undertaken in golden 
retrievers with muscular dystrophy (GRMD), a model with a spontaneously occurring 
splice site mutation in the dystrophin gene [68].  This model has increasingly been used 
as a preclinical model for various therapeutic approaches, including cell-based therapy.  
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Despite the successes of cell transplantation in mice, the GRMD based experiments fall 
in line with the human trials as both were unable to achieve a therapeutic implantation of 
myoblasts (Kornegay JN, unpublished observations) [39, 40].  Because of the negative 
human findings, clinical trials were halted in the late 1990’s. 
Satellite cells occupy an anatomical niche between the sarcolemma of the 
myofiber and the basement membrane. This position is what allowed satellite cells to be 
first identified in 1961 by Katz and Mauro [69]. The satellite cells must be able to remain 
quiescent when there is no need for muscle repair and then activate quickly to provide 
numerous myoblasts needed to repair damage. Furthermore, they must be able to self-
renew to maintain the satellite cell population [34].  
The source of satellite cells for most muscles during development is the somites [70-
72].  After myogenic induction in the somite, Pax3 and MyoD regulate the embryonic 
myoblast populations during migration and proliferation.  Once muscles have been 
formed, myoblasts transition to a population of quiescent satellite cells. Work with Pax3- 
or c-Met-null mice has shown a failure of muscle development, save for a few myoblasts 
in the limbs [50]. These lone myoblasts are positive for CD34 and Flk1, markers 
associated with hematopoietic and endothelial cells. Pax7-null mice have no adult 
satellite cells, and mononuclear cells isolated from muscle do not undergo myogenesis in 
culture [73, 74].   
The satellite cells and myoblasts are known to express several transcription 
factors which determine, maintain and differentiate the myogenic lineage.  In the adult 
animal, Pax7 is the primary regulator [74, 75].  Expression of Pax7 protein maintains 
cells in an undifferentiated state and inhibits the expression of genes (MyoD, Myf5, 
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Myogenin and Mrf4) that regulate the differentiation process.  These myogenic 
regulatory factors are up-regulated in sequence during the proliferative phase after 
satellite cell activation [54, 66, 76, 77].  They promote expansion of the satellite cells and 
myoblasts but also encourage terminal differentiation.  Once myogenin protein is 
expressed in myoblasts, there is a cascade towards terminal differentiation and formation 
of multinucleated myotubes.  At this point, terminal differentiation proteins, such as 
utrophin, are strongly expressed to help the cells execute functions of muscle fibers [78, 
79].  Studying the progression of this cascade of expression provides insight regarding 
genes that drive myogenic differentiation in dogs and allows characterization of these 
cells in culture. 
Satellite cells and myoblasts can be readily obtained through small muscle 
biopsies.  Any isolation technique requires the muscle fibers to be separated to expose the 
satellite cells.  This requires the use of enzymes, typically collagenase and trypsin [80, 
81].   Digested material is then passed through sieves to remove muscle fibers and collect 
mononuclear cells in the remaining fluid.  From here there are two basic approaches to 
the isolation of satellite cells, preplate isolation and flow assisted cell sorting (FACS). 
The preplate technique is based on the adhesion of cells to polystyrene tissue 
culture dishes and involves repeated decanting and culture of the supernatant [80, 81]. 
Satellite cells are generally quiescent, becoming activated only after a stimulus signals 
the need to repair damage. Thus, in the initial culture plating, these cells are non-adherent 
and remain in the decanted supernatant.  Other undesired cell types, such as fibroblasts 
and macrophages, are persistently active, performing functions within the muscle. These 
activated cells adhere rapidly to polystyrene and remain on the surface during the initial 
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platings when the media is decanted [65, 81]. This preplating technique ultimately results 
in a satellite-cell-enriched, but nonetheless heterogeneous, mixture of cells.  
FACS is a technique that depends on the use of fluorescently labeled antibodies to 
surface markers, dyes, and light scattering properties to identify and characterize specific 
properties of cells [82, 83].  To sort viable cells, a repertoire of antibodies must be 
available for surface markers on the cell.  This antibody repertoire exists for mice but is 
generally lacking for canine models. NCAM1 (CD56) has been used to sort myoblasts 
isolated from canine muscle in the past [84, 85].  This protein is expressed on activated 
satellite cells through multinucleated myotubes [78].  Syndecan4 has also been 
characterized on canine satellite cells [86]. Little else has been done to characterize the 
GRMD satellite cells with antibodies.  
Primary muscle cell cultures have been characterized for mice, humans and dogs.  
In these studies, isolated cells were analyzed for differential properties under growth and 
differentiation conditions [83, 87-92].  There has been little difference in the expression 
of surface markers and internal proteins between dystrophic and normal myoblasts.  A 
few differences in proliferation and differentiation have been found between normal and 
dystrophic cells from human and mouse but not canine myoblasts [87-89, 91, 92].  
Recent reports have characterized several muscle specific proteins, including desmin, 
myosin heavy chain, and MyoD, in primary cultures from normal and GRMD cells and 
found no significant differences between the two groups [57, 86].  The mRNA gene 
expression profile of dystrophic and normal satellite cells and myoblasts has not been 
studied.    Here, we present an mRNA and immunohistochemistry based analysis of 
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myogenic cells from normal and GRMD dogs during growth and differentiation to 
analyze their myogenic potential in cell based therapies. 
 
  
Materials and Methods 
Isolation of satellite cells and myoblasts 
 Cell cultures were established from biopsies 
taken sterilely at surgery from the vastus lateralis 
muscle of the pelvic limb from 2 to 4 month old normal 
(n =6) and GRMD (n =6) dogs (Table 2.1).  Muscle 
samples were placed in a bath of PBS containing 
penicillin, streptomycin and amphotericin B, on ice.  
Samples were brought into a sterile tissue culture hood 
for breakdown.  Using a razorblade and forceps, fibrous 
connective tissue was removed.  Tissue was minced to a 
fine consistency, less than 1mm, to allow pieces to fit 
though the end of a pipette and then digested with collagenase in growth media for one 
hour.  Every 15 minutes, the tissue was triturated through the narrow opening of a pipette.  
After one hour, the digested tissue was spun down at 800 g for 2.5 min. The supernatant 
was removed and the pellet was rinsed with PBS and re-spun; pelleting and rinsing was 
done twice.  The myofibers were then treated with 0.25% trypsin solution for 30 min, 
with trituration every 15 min, to digest the laminin layer and release the satellite cells.  
The digested material was then passed through 100 and 40 µm screens to remove fiber 
debris and isolate the cells.  Cells were rinsed twice with PBS and put through the 
Table 2.1. Normal (blue) and 
GRMD (red) study groups.  Desmin 
and Pax7 staining percentages 
from preplates 5 and 6. 
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preplate procedure.  Cells were plated on tissue culture plastic for one hour to remove 
rapidly adherent cells.  Unattached cells were transferred to a 0.1% gelatin coated plate 
for 24 hrs (preplate 1), and then on to a new plate every 24 hours for up to 5 plates 
(preplates 2-6).  Cells were cultured in growth media consisting of high glucose DMEM 
(Sigma) with 20% FBS and 100units/mL penicillin and 100ug/mL streptomycin. 
Flow Cytometry  
Cell cultures were established and passed once.  Cells were removed from the culture 
surface using 0.5% trypsin with 0.25% EDTA for two minutes.  Cells were sequentially 
centrifuged at 1000 g and washed twice with PBS; re-suspended in FACS Fix buffer, 1% 
formaldehyde, placed on ice for 10 min, spun down and resuspended in FACS Buffer, 
stained with antibodies to NCAM-1 (5.1H11 from DSHB, Iowa  City, Iowa) and allowed 
to sit on ice for 30 minutes, washed twice with FACS Buffer, stained with anti-mouse-
APC secondary, anti-canine CD45-FITC (AbD Serotec, Oxford, UK) and anti-canine 
CD34-PE (BD Pharmingen, Franklin Lakes, NJ) and allowed to bind antibodies for 30 
minutes; washed twice with FACS Buffer and resuspended in 1mL of FACS Buffer; and 
run through a Cyan flow cytometer (Dako, Carpinteria, CA).    
Cell Differentiation 
Cells were plated on gelatin coated 96 well plates, for 1 hr with 0.1% gelatin in sterile 
water for immunohistochemistry (IHC) experiments or T25 flasks (Corning, Corning, 
NY) for mRNA collection at a density of 10,000 cells/cm
2
. Cells were allowed to adhere 
for 24 hours in growth media, 20% FBS in DMEM. Growth media was then replaced 
with 2% horse serum in DMEM differentiation media.  Medias also contained 100 units 
per mL penicillin-streptomycin.  Cells were fixed for IHC or 200,000 cells were collected 
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for mRNA at Day 0, Day 3, Day 5, and Day 7.  Cells (~ 200,000) for telomerase 
expression were collected from Day 0, spun down, decanted and snap frozen in liquid 
nitrogen and stored at -80
o
C.   
Cell fusion studies were conducted to quantify the ability of cultures to form 
multinucleated myotubes when presented with a differentiation stimulus, low serum 
media.   Cells were plated at 10,000 cells per cm
2
 in T25 flasks.  Cells were plated in 
growth media and switched to low serum media at 48 hrs.  Hoechst dye was used to label 
nuclei and fluorescent images were overlaid with brightfield images to count nuclei 
(Figure 2.6 A, B, & C).  Nuclei involved in cell fusions were quantitated and expressed 
as a percentage of total nuclei involved in cell fusions. Cultures were imaged at Days 1, 
3, 5, and 7 with brightfield and DAPI filter.  Cells were temporarily stained with Hoechst 
33342, 1 µg per mL, to identify nuclei. The total number of nuclei and nuclei associated 
with multinucleated myotubes were quantitated with the aid of ImageJ (NIH) software.  
Images were taken with an Olympus IX81 microscope with a Hamamatsu Orca R2 digital 
camera system with a 10X lens. 
Sample Collection and Processing  
Cells collected for IHC were fixed for 10 minutes in 4% PFA, permeabilized with 
0.5% Triton-X-100 in 1x PBS for 10 minutes, blocked with 2% FBS in PBS for 1 hour 
and stained with antibodies at 4
o
C for four hours and then rinsed with three rounds of 2% 
horse serum in PBS for 5 minutes.  Primary antibodies include: Pax7 (DSHB, Iowa City, 
IO), MyoD (Dako, Carpenteria, CA), Myogenin (DSHB, Iowa City, IO), Myosin Heavy 
Chain (DSHB, Iowa City, IO), Desmin (Sigma, St. Louis, MO).  Secondary antibody 
(Invitrogen, Carlsbad, CA) was applied at 1:500 for one hour at 4
o
C.  Cells were rinsed 
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with three rounds of 2% horse serum in 1x PBS for 5 min and incubated with PBS 
containing 1 µg/mL Hoechst dye for 10 minutes and then immediately imaged with the 
camera system described above.   
Cells for mRNA isolation were trypsinized, spun down, washed with 1 mL of 1x 
PBS twice and resuspended in 100 µL of 1x PBS.  Lysis buffer (Applied Biosystems, 
Carlsbad, CA), 100 µL, was added to the cells and briefly vortexed before storage at -
20
o
C.  Total RNA was isolated in an RNA purification tray, using the ABI Prism 6100 
Nucleic Acid Prepstation (Applied Biosystems, Carlsbad, CA) following the 
manufacture’s protocol. Real-time RT-PCR amplifications were performed using a 
published protocol [93]. Single reactions with canine β-actin, Pax7, MyoD, Myogenin, 
and Utrophin (Table 2.2) were measured by the 7300 sequence detector in each well of a 
96 well plate.  Data analysis was done by ddCt method [94, 95]. 
Telomerase Expression  
 Telomerase expression experiments used the TeloTAAGGG Telomerase PCR 
ElisaPlus kit (Roche Diagnostics, Indianapolis, IN).  Telomerase studies were conducted 
to determine the quantity of telomerase that is active in the isolated normal and GRMD 
cultures.  Immortalized cell lines, HEK293 and C2C12, along with high and low control 
templates were used to determine relative telomerase activity (RTA).  Samples were 
Table 2.2: Primer and probe sequences for relative gene expression quantitation. 
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processed per kit instuctions.  PCR was done using a Verti 96 well PCR machine 
(Applied Biosystems, Carlsbad, CA) using the protocol provided with kit instructions. 
Statistics 
 Results from biological samples, including immunohistochemistry, mRNA, cell 
fusion and relative telomerase activity were tabulated and error bars were calculated as 
standard error.  P-values were calculated using a two-tailed students T-test.  
 
Results 
Cultures were visually indistinguishable between normal and GRMD dogs.  These 
cultures consisted of small fairly rounded cells with one to three visible contacts with the 
cell culture plate.  Small clusters of cells were seen after 2-3 days in culture.  After three 
days in culture, cells would begin to elongate with two obvious points of connection and 
a few multinucleated cells would appear.  Cultures of each genotype were put through the 
preplate procedure.  More cells adhered to the culture plates from GRMD samples, 
especially in early preplates, presumably due to increased numbers of activated 
myoblasts, fibroblasts and macrophages.  A portion of cells from preplates 5 and 6 were 
stained for desmin and Pax7 protein expression.  In all cases the percentage of desmin 
positive cells was higher than the percentage of Pax7 positive cells (Table 2.1).   
Cells collected from each of the preplates, PP1-PP6 were subjected to mRNA 
analysis for the genes in Table 2.2. The later preplates showed elevated levels of all the 
myogenic associated genes for both normal and GRMD cultures (Figure 2.1).  GRMD 
and normal cultures had minimal expression of Pax7 and Myogenin in the early preplates, 
with expression rising in later preplates. GRMD cultures demonstrated low levels of 
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MyoD in early preplates 
and again rising levels in 
later preplates while 
normal cultures showed 
elevated levels of MyoD, 
~40% of PP6, in the early 
preplates.  Utrophin levels 
for both cultures started at 
about half that of the later 
preplates and increased in 
the later preplates.  
Cultured cells 
were also analyzed for 
expression of NCAM-1 
surface marker through 
FACS analysis.  
Approximately 85% of both 
normal and GRMD cells 
stained strongly for 
NCAM-1.  Separate groups 
of cells also stained for 
CD45, the pan 
hematopoietic marker, and 
Figure 2.2.  Flow cytometry of primary canine satellite cells and 
myoblasts.  Cells are stained for A) NCAM1 and CD45 and B) CD34 
and CD45.  Cells are from a 4 month old normal dog and from 
preplates 5 and 6.  X-axis CD45 (A & B); Y-Axis NCAM-1 (A), CD34 (B). 
Figure 2.1. Preplate mRNA expression for Pax7, MyoD, Myogenin 
and Utrophin.  Cells collected from passage 1 or 2. mRNA for genes 
of interest is relative to β-actin control mRNA. 
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showed very little contamination with hematopoietic cells (Figure 2.2 A & B).  Cells  
showed no discernible expression of CD34 but were strongly positive for NCAM-1 
(Figure 2.2 B).   
Isolated cells were stained for myogenic associated proteins in growth and 
differentiation conditions, (Figure 2.3).    Transcription factors Pax7 and MyoD were 
readily visible in growth cultures.  Myogenin, the transcription factor responsible for 
commitment to terminal differentiation, was only identified in rare nuclei in growth 
cultures but present in differentiation cultures on Days 3, 5, and 7.  Desmin was seen in 
growth and differentiation cultures. Protein for the key myogenic factors Pax7, MyoD, 
and myogenin along with a terminal differentiation associated protein, myosin heavy 
chain, where quantified (Figure 2.4).  At Day 1, both normal and GRMD cultures had 
very similar numbers of nuclei expressing Pax7, MyoD, and myogenin and similar 
numbers of nuclei in cells that express myosin heavy chain.   
From this point, normal and GRMD cultures began to diverge.  Pax7 protein 
levels decrease and become significantly different (p=0.03) by Day 5, with normal 
cultures having a greater percentage of Pax7 positive nuclei (Figure 2.4A). MyoD 
expression increased at Day 3 in both cultures but decreased from Day 3 to Day 5 in 
A B C D 
Figure 2.3 IHC for satellite cell and myoblast associated proteins.  Pax7 growth (A), Desmin growth 
(B), MyoD growth (C), Myogenin differentiation (D).  Cells are from preplates 5 and 6 from a normal 
dog. All images were taken with a 10x objective. 
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normal cultures while GRMD levels continued to increase at Day 5 (Figure 2.4B).  
Positive MyoD nuclei percentage was significantly different on Day 5 (p=0.007).  
MHC levels increased in both cultures over the 5 days but GRMD cultures 
showed a significantly greater number of nuclei associated with MHC positive cells on 
Day 3 (p=0.002) and Day 5 (p=0.001) (Figure 2.4C).   Myogenin levels also increased in 
both cultures over the 5 days where GRMD cultures showed a significantly greater 
number of positive nuclei on Day 3 (p=0.001) and Day 5 (p=0.004) (Figure 2.4D).   
The mRNA results of cultures derived from the late preplates, PP5 and PP6, of 
normal and GRMD samples showed that the late preplates express higher levels of 
myogenic associated mRNAs than early preplates, (Figure 2.1).  GRMD cultures showed 
Figure 2.4.  Percentage of nuclei expressing or associated with cells expressing myogenic 
proteins. Pax7 expression (A), MyoD (B), Myosin Heavy Chain (C), and Myogenin (D). 
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very little myogenic associated mRNAs other than utrophin in there early preplates while 
normal samples showed higher levels of everything except myogenin.   
Analysis of mRNA from cells isolated from normal and GRMD cultures, PP5 and 
PP6, that were collected in growth phase, Day 0, were indistinguishable between normal 
and GRMD samples for all of the mRNAs, (Figure 2.5).  Pax7 expression immediately 
dropped off between Day 0 and Day 3 for GRMD while normal cultures had an up-tick in 
expression.  After Day 3, both cultures showed a decrease in Pax7 mRNA expression.  
From Day 3 to Day 7, normal Pax7 mRNA levels were significantly higher (p<0.002).   
MyoD expression was up-regulated in normal cultures while dropping off in GRMD 
Figure 2.5.  Relative mRNA expression for differentiation cultures. Cultures of normal and GRMD 
cells  examined for Pax7 (A), MyoD (B), Utrophin (C), and Myogenin (D).  Expression is measured 
against Day 0 mRNA levels, 100%, and followed for a 7 day differentiation.  All expression is 
relative to β-actin mRNA internal controls. 
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dogs, showing significant difference on Days 5 and 7 (p<0.001) (Figure 2.5B).  Utrophin 
mRNA expression levels increased similarly for both GRMD and normal samples 
through Day 7 but were not significantly different at any point (Figure 2.5C).  
Myogenin mRNA was strongly up-regulated in normal cultures while GRMD cultures 
showed a relatively moderate increase through Day 5, followed by a decrease in 
expression by Day 7 (Figure 2.5D).  Normal samples were significantly higher on Days 5 
and 7 (p<0.001). Cell fusion studies showed that both normal and GRMD cells formed 
multinucleated myotubes (Figure 2.6 A, B, & C).  GRMD samples had a significantly 
greater (p=0.004) percentage of nuclei associated with myotubes on Days 5 and 7, ~17% 
for both days,  than normal samples, ~8% for both days.  GRMD cultures showed greater 
Figure 2.6. Cell fusion under differentiation.  Nuclei (red) labeled with Hoechst dye and overlaid 
with brightfield images.  Images taken at Days 3 (A), 5 (B), and 7 (C). Cells containing 3 or more 
fused nuclei quantitated and expressed as % Nuclei involved in cell fusions (D). Images taken with a 
10× objective. 
25 
 
capacity than normal cultures to form cell fusions at Day 5 and continuing through Day 7 
(Figure 2.6D).  
Telomerase activity between normal and GRMD cultures was statistically 
indistinguishable (Figure 2.7).  RTA levels for all primary isolates were below the levels 
of the immortalized cell lines C2C12 and HEK293.  
 
Discussion 
The GRMD model is of great importance to the development and testing of 
therapies, whether they are pharmacological, genetic or cellular in makeup.  Testing of 
cell-based therapies requires a more in-depth understanding of the cells that are primarily 
responsible for regenerating muscle, the satellite cells.  Previous studies in dogs have 
found little if any difference between normal and diseased cultures of satellite cells [57, 
85, 86].  Studies in mice have indicated that satellite cells isolated from the mdx model 
have a propensity to differentiate more quickly than their normal counterparts [92]. 
Published canine studies evaluated protein expression and growth rates to characterize 
Figure 2.7. Relative telomerase activity in isolated primary cells and cell lines. 
Normal samples are in blue, GRMD samples in red, cell lines in violet and controls in 
green. 
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the cells.  The characterization of these cells focused on the growth phase of cultures or at 
a single point at the end of the differentiation protocol.  This provides some information 
on the basic character of the satellite cell, but there is more information to be found 
characterizing cells throughout the differentiation period at both the gene transcriptional 
and protein levels. 
 Our study evaluated the mRNA expression level of Pax7, MyoD, myogenin, and 
utrophin though a seven day differentiation period.  We then characterized Pax7, MyoD, 
myogenin and myosin heavy chain expression with immunohistochemistry (IHC).  Pax7 
is a transcription factor known to be the master regulator of the satellite cell [34, 75, 96, 
97].  Its expression inhibits the differentiation of satellite cells and myoblasts.  MyoD is 
the second transcription factor and its expression is associated with activated satellite 
cells and proliferating myoblasts [54, 57, 78, 97]. MyoD expression follows that of Pax7 
and is co-expressed for a time.  Myogenin is one of several transcription factors 
associated with terminal differentiation of cells and the next transcription factor in this 
series [54, 77, 97].  Utrophin is a structural protein expressed in the cytosol of the cell 
[79].  Myosin heavy chain is also expressed during terminal differentiation and acts as a 
key component of the actin myosin network in functional muscle fibers [98]. 
 Preplates from normal and GRMD dogs were analyzed for several transcription 
factors and utrophin expression at each of the preplate steps, PP1 to PP6 (Figure 2.1).  
Expression of mRNA at each pre-plate, using the β-actin housekeeping gene as a control, 
was compared to PP6 levels, where the highest purity of satellite cells is expected [81, 83, 
99].  The difference between the critical threshold of the β-actin and that of the gene of 
interest was the basis for analysis and comparison.  Cultures for both normal and GRMD 
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showed low levels of Pax7, MyoD and myogenin in the early preplates, with these levels 
increasing in the later preplates, as expected. GRMD cultures had lower expression of the 
transcription factors in the early pre-plates than normal cultures.  This could be due to 
larger amounts of other cell types found in GRMD biopsies, such as macrophages and 
fibroblasts[81].  Utrophin levels decreased slightly in GRMD samples from PP1 to PP3 
and increased in the later preplates (Figure 2.1).  This could be due to cells in the biopsy 
undergoing terminal differentiation and expressing more utrophin at the time of isolation. 
These cells would also be strongly activated and “sticky” coming out in the early 
preplates. 
 Cells were also subjected to flow cytometry to assess purity of the cultures in 
regard to a surface marker, NCAM1, which has been used in the past to purify myoblast 
cell cultures.  The level of NCAM1 expression on both normal and GRMD cultures was 
85% with little contamination by macrophages as determined by CD45 co-staining 
(Figure 2.2A).  CD34 is known to be expressed on satellite cells but expression drops off 
in culture.  These cultures showed very little expression of CD34 (Figure 2.2B).  Purity 
of cells obtained via the preplate procedure is comparable to that obtained via flow 
cytometry for NCAM1, in previous studies [85]. 
 Cultures were also evaluated for expression of Pax7, MyoD, Myogenin, and 
desmin protein using IHC. Desmin is a marker for myoblasts and newly formed 
myotubes but is not reliably expressed in satellite cells [83, 100].  Therefore, desmin is  is 
not the best marker to determine the stem cell potential of a culture.  However, its 
expression is still commonly determined to determine the purity of cultures.  Pax7 is 
strongly expressed in satellite cells, regulating the stem cell state of these cells, and 
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serves as a better marker for the purity of cultures.  This is especially true when 
considering cells to be used for transplantation purposes.  Normal and GRMD cultures 
from late preplates, PP5 and PP6, were stained for desmin and Pax7.  Desmin expression 
ranged from 100% to 88% expression in both cultures (Table 2.1).  Pax7 expression was 
typically at 90 to 80%, with a range of 97% to 72% with.  While the percentage of Pax7 
positive cells was lower than those positive for desmin in all cases, .  there were, no 
significant differences in percentages of cells expressing Pax7 were detected between 
normal and GRMD cultures in undifferentiated cultures. 
 Our studies provide static pictures of cells in a singular state just after isolation 
with the preplate procedure.  However, satellite cells do not remain in a static state but 
instead respond to the environment and differentiate when called upon.  Previous studies 
on mdx mice showed accelerated differentiation of mdx cultures looking at MyoD and 
myogenin protein expression under growth and differentiation conditions [92].  Studies of 
the changes in satellite cell regulation in vitro have not been reported before at the 
mRNA level.  Examination of the transcription factors that regulate this process is needed 
to better characterize the GRMD model.  Genes of interest were studied in cultures 
subjected to a differentiation procedure with low serum conditions carried out for seven 
days.   
 In the case of Pax7 mRNA, normal cultures showed a slight increase of the 
expression level, up to ~120% of levels before cells were subjected to a differentiation 
procedure. GRMD dogs did not demonstrate an increase in Pax7 mRNA levels.  This can 
be seen at Day 3 in Figure 2.5A. From Day 3 to Day 7, expression levels decreased at 
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similar rates in both cultures.  Normal cultures lost Pax7 mRNA expression before those 
from GRMD dogs.  
 MyoD mRNA expression was distinctly different over the course of the 
differentiation procedure in normal vs. GRMD cultures.  Normal cultures show an up-
regulation of the mRNA levels, to almost 300% of Day 0, while GRMD cultures showed 
a down regulation of MyoD expression, to around 35% of Day 0 ( Figure 2.5B).  Since 
MyoD is associated with the proliferation of satellite cells and myoblasts and is lost when 
cells differentiate, it would be reasonable to conclude that the normal myogenic cells are 
continuing to proliferate while GRMD cells are undergoing more rapid differentiation.   
 Myogenin levels also increased in normal cultures over the preplates, while not 
changing in GRMD cultures (Figure 2.5C).  This is counter to the protein expression 
data where GRMD cells show a greater percentage of nuclei expressing myogenin, 
compared to normal cells, as the cells differentiate, (Figure 2.4D). 
 Utrophin mRNA levels were similarly increased in both normal and GRMD 
cultures.  Since utrophin expression not up regulated until fairly late in the differentiation 
cascade, relative to the previously noted transcription factors, it is not surprising that both 
cultures demonstrate similar levels of utrophin.   
 Our findings on mRNA levels were reinforced by the results from the changes 
observed in the percentages of cell expressing Pax7, MyoD, myogenin and MHC over a 5 
day differentiation period (Figure 2.4).  On Day 1, percentages of nuclei positive for all 
of the transcription factors did not between normal and GRMD cultures.  Percentages of 
nuclei found in cells expressing MHC were also indistinguishable between normal and 
GRMD cultures.  The percentage of Pax7-positive nuclei decreased in both GRMD and 
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normal cultures (Figure 2.4A).  On Day 5, normal cultures had significantly higher 
expression percentages than GRMD cultures, pointing towards enhanced differentiation 
of GRMD cultures. 
 MyoD protein expression percentages increased in both normal and GRMD 
cultures to Day 3.  By Day 5, normal cultures had lower levels and GRMD cell 
expression increased (Figure 2.4B).  Myogenin positive nuclei percentages started out 
around 2% on Day 1 with normal cultures increasing to 23% on Day 3.  GRMD cultures 
had a much greater increase to 55% on Day 3, significantly more than normal cultures 
(p=0.001).  By Day 5, both cultures maintained the percentages of nuclei expressing 
myogenin (Figure 2.4D). Finally, MHC-associated nuclei started off low on Day 1 and 
increased on Days 3 and 5 for both cultures.  Expression percentages for GRMD cultures 
were significantly higher on Days 3 and 5 (Figure 2.4C).  These results point toward an 
enhanced capacity of the GRMD cultures to differentiate even though growth phase 
cultures are indistinguishable between normal and GRMD cultures. 
 This propensity for greater differentiation can be seen in the results from cell 
fusion experiments (Figure 2.6).  Day 0 normal and GRMD cells were indistinguishable 
from one another.  At Day 3, cells were noticed undergoing fusion events (Figure 2.6A).  
There was no difference between normal and GRMD cultures in the percentage of fused 
nuclei at Day3.  However by Day 5, GRMD cultures demonstrated an increased number 
of fusion events over normal dogs (p=0.003) (Figure 2.6D). 
Early studies by Blau and colleagues utilizing isolation techniques demonstrated 
decreased numbers of satellite cells in mdx mice [87, 101].  However, in a subsequent 
study by this same group, similar numbers of Pax7 positive satellite cells were seen in 
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mdx and normal mice at 8 and 60 weeks [102].  These conflicting reports may have more 
to do with the methods used in isolation of cells rather than the disease state of the 
muscle.  The 2010 study looked at the effect of telomerase deficiency on disease severity 
[102].  Cells that have undergone several rounds of cell division end up with shortened 
telomeres unless the telomerase enzyme is expressed in the cell.  This allows cells to fall 
into a senescent state turning the mild mdx phenotype into a much more severe form of 
the disease.  Reduced numbers of satellite cells were seen only in telomerase-deficient 
mice [102].     
In the study conducted here, we assessed cells from young dogs, approximately 
four weeks of age, as this is the age at which cells for autologous cell modification and 
eventual therapy would be collected.  Satellite cells should not be reduced in dystrophic 
muscle at this early age.  Indeed, GRMD and normal cells expressed telomerase at similar 
levels (Figure 2.7).   This implies that GRMD cells are capable of maintaining the 
telomere length to a similar degree as normal cells, possibly preventing them from 
slipping into senescence.  However, differences in telomerase activity might have been 
seen had samples from older GRMD dogs been evaluated.   
Given these mRNA, protein, and cell fusion results, we conclude that GRMD 
cultures are in a more advanced differentiation state upon isolation from whole muscle 
tissue.  Satellite cells and myoblasts may not have the time to become quiescent before 
again being activated, in the context of regenerating muscle.  Satellite cells from normal 
and GRMD biopsies appear to be equivalently capable of proliferation but when 
subjected to differentiation, GRMD cells may have a greater propensity to differentiate.   
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As cells differentiate down the path to myotube formation, transcriptional and 
translational control of myogenic associated genes are altered.  The cells isolated from 
the GRMD samples came out of tissue that has a larger number of activated satellite cells 
and myoblasts at various stages of differentiation, unlike normal satellite cells, which 
should be isolated at a quiescent stage.  The layers of transcriptional control are likely 
altered in GRMD cultures to something downstream towards myotube formation when 
compared to normal cultures.  Evidence for this can be seen in the altered mRNA 
transcript levels for the myogenic regulatory factors, Pax7, MyoD, and myogenin.  
Mechanisms for these differences are not completely understood and were not the subject 
of our studies. 
These findings have implications for cell based therapies that would rely on 
isolating and manipulating the satellite cell population from GRMD dogs.  Cells that are 
more prone to differentiate in culture may not be able to contribute to future myogenic 
repair of muscles as effectively as normal cells, leaving a need to continue the study of 
allogenic stem cell sources to repair and replace damaged and atrophying muscle tissue.    
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Chapter 3 
Polystyrene-Coated Micropallets for Culture and Separation of Primary Muscle 
Cells 
 
Introduction 
 Despite identification of a large number of adult stem cell types, current primary 
cell isolation and identification techniques yield heterogeneous samples, making detailed 
biological studies challenging. To identify subsets of isolated cells, technologies capable 
of simultaneous cell culture and cloning are necessary. Micropallet arrays, a new cloning 
platform for adherent cell types, hold great potential. However, the microstructures 
composing these arrays are fabricated from an epoxy photoresist 1002F, a growth surface 
unsuitable for many cell types. Optimization of the microstructures’ surface properties 
was conducted for the culture of satellite cells, primary muscle cells for which improved 
cell isolation techniques are desired. A variety of surface materials were screened for 
satellite cell adhesion and proliferation and compared to their optimal substrate, gelatin-
coated Petri dishes. A 1-µm thick, polystyrene copolymer was applied to the 
microstructures by contact-printing. A negatively charged copolymer of 5% acrylic acid 
in 95% styrene was found to be equivalent to the control Petri dishes for cell adhesion 
and proliferation. Cells cultured on control dishes and optimal copolymer-coated surfaces 
maintained an undifferentiated state and showed similar mRNA expression for two genes 
indicative of cell differentiation during a standard differentiation protocol. Experiments 
using additional contact-printed layers of extracellular matrix proteins collagen and 
gelatin showed no further improvements.  
Copyright: This chapter is reprinted with permission from Springer, liscense number 2883930675884. 
Polystyrene-coated micropallets for culture and separation of primary muscle cells. 
Detwiler DA, Dobes NC, Sims CE, Kornegay JN, Allbritton NL.Anal Bioanal Chem. 2012 
Jan;402(3):1083-91. Epub 2011 Dec 9. 
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Stem cells hold the promise of revolutionizing tissue engineering and other areas 
of regenerative medicine. Satellite cells, which are muscle progenitor cells, are a stem 
cell of great interest to the research community surrounding the family of diseases known 
as muscular dystrophy [2-5]. These diseases lead to a loss of muscle strength and/or 
function. The most severe form of muscular dystrophy, Duchenne muscular dystrophy 
(DMD), presents a progressive loss of strength in skeletal muscle and leads to muscle 
atrophy. Complications from progressive muscle deterioration limit the lifespan of 
affected individuals to two to three decades. Several animal models for DMD have been 
developed, with the two most influential being the mouse (MDX – muscular dystrophy 
X-linked) and the canine (GRMD - Golden retriever muscular dystrophy). The mouse 
model has been used extensively to examine the underlying disease physiology [6, 7]. 
The canine model, GRMD, better mimics the human disease in severity and is a size 
relevant model [8, 9]. Currently there are no clinically available therapies that correct, 
halt or limit the progression of the disease, though clinical trials are underway [10-12].  
One therapeutic approach to treat DMD uses transplantation of satellite cells to 
correct or replace the cells responsible for muscle tissue regeneration. This approach, in 
principle, has the ability to restore lost muscle mass in late-stage patients. Currently, 
techniques to isolate and purify satellite cells and other muscle progenitor cells such as 
myoblasts have been based primarily on the preplate method and flow cytometry. The 
preplate technique is based on the adhesion of cells to polystyrene tissue culture dishes 
and involves repeated decanting and culture of the supernatant [80, 81]. Quiescent 
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satellite cells become activated only after a stimulus signals the need to repair damage. 
Thus in the initial platings, these cells are non-adherent and remain in the supernatant.  
Other undesired cell types, such as fibroblasts and macrophages, are programmed to 
actively perform functions within the muscle and adhere rapidly to polystyrene, 
remaining on the surface during the initial platings [65, 81]. This preplating technique 
ultimately results in a satellite-cell-enriched but nonetheless heterogeneous mixture of 
cells.  
Alternatively, flow cytometry protocols are capable of generating populations of 
increased purity, but require functional antibodies specific to cell surface markers. 
Particularly for canine cells, which at present lack an adequate repertoire of antibodies for 
selection, the technique’s ability to sort and purify the desired cells remains limited and 
requires further cell characterization. Thus, new technologies are needed to more 
effectively sort and purify primary canine satellite cells (PCSCs).   
The advent of microfabricated devices has enabled novel investigations of 
biological properties. Micropallet arrays have provided a means to clonally culture and 
isolate cells based on a wide range of characteristics, including the presence or absence of 
fluorescently tagged proteins, and additional criteria not available to flow cytometry, 
including cell morphology, growth rate, and other dynamic behaviors [58, 60]. With the 
large number of microstructures available on an array, the cloning and isolation of 
moderate to large numbers of cells is greatly simplified over standard tissue culture 
cloning techniques. Micropallet arrays have previously been used to clone and sort tumor 
cells, murine embryonic stem cells, and other cell lines [58, 60, 62, 63]. While numerous 
generations of these cell lines have been adapted to cell culture conditions, more 
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physiologically relevant primary cells are not so adept at adhesion to artificial surfaces. 
This creates the need for a tailored culture surface to meet the requirements of these 
primary cells.  
In this research, we have optimized the surface of micropallets for PCSCs, the cells 
responsible for maintenance and regeneration of skeletal muscle. Contact printing of the 
micropallets was evaluated for its capacity to generate a suitable surface for the culture of 
PCSCs and to lay the groundwork for developing procedures applicable to other primary 
cell types [62, 64, 103]. The long-term goal of this work is to utilize the micropallet 
arrays to sort PCSCs using a variety of parameters and shorter timescales not available 
through traditional cloning techniques or flow cytometry.  This is expected to enable 
more efficient characterization of these cell types than is currently possible, as well as 
identify new cell subsets not previously identified. 
 
Materials and Methods 
Polymer and Copolymer Synthesis 
 Various polymers were synthesized, including neutral polystyrene (PS) and 
positive and negative copolymers. Briefly, components (Table 3.1) were weighed and 
Table 3.1 Composition of copolymers by wt% 
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mixed in a fume hood and placed in a 60 C water bath overnight to polymerize. 
Negatively charged copolymers containing > 2.5% acrylic acid (AA) precipitated out of 
the toluene solvent forming a solid layer on the bottom of the reaction vessel. After 
reactions using these concentrations and polymers, the remaining solvent was decanted 
and replaced with an equal amount of tetrahydrofuran (THF) (Sigma, St Louis, MO) to 
solubilize the copolymer. For the 2.5% AA in PS copolymer, only a partial copolymer 
layer precipitated from the toluene, thus the toluene was evaporated from the mixture on 
a 60 C hotplate to recover any non-precipitated copolymer. Once the toluene was 
removed, an equal volume of THF was added to dissolve the 2.5% AA in PS copolymer 
completely. Positively charged copolymers containing 4-vinyl pyridine (4VP) were fully 
soluble in toluene, so replacing toluene with THF was not necessary. 
 
Cell Isolations and Culture  
 PCSCs were isolated from muscle biopsies of the vastus lateralis of a normal dog 
in the GRMD colony at University of North Carolina at Chapel Hill (UNC-CH). Cells 
were isolated from biopsies as previously described with minor modifications [65, 81]. 
Briefly, biopsy material was finely minced and digested with collagenase in growth 
media, 16.5% FBS in Dulbecco’s Modified Eagle Media (DMEM), for 6-8 h. Material 
was rinsed and digested with 0.05% trypsin for 1 hr with agitation every 15 min. Material 
was then passed through a 100 µm screen followed by a 40 µm screen and plated on 
0.1% gelatin (Millipore, Billerica, MA) coated tissue-culture-treated polystyrene (TC) 
Petri dishes (BD Falcon, Franklin Lakes, NJ). Six successive platings with the preplate 
procedure resulted in enriched populations of PCSCs, with cells from plates 4, 5, or 6 
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used in the current experiments [81, 99]. To confirm the presence of PCSCs, 1000 cells 
from passage two of preplate 5 were fixed and stained with anti-desmin antibodies and 
counterstained with Hoechst dye. Desmin, a marker for PCSC, was detected in 94% of 
the cells. The enriched cell populations were further cultured in uncoated TC dishes in 
16.5% fetal bovine serum in Dulbecco’s Modified Eagle Medium (DMEM), with 1% 
penicillin-streptomycin defined as standard growth conditions [55]. To differentiate the 
PCSCs, the cells were cultured in 2% horse serum (Invitrogen, Carlsbad, CA) in DMEM 
with 1% penicillin-streptomycin, defined as standard differentiation conditions [55]. 
Photoresist and Polymer Film Fabrication 
Photoresist, 1002F, was prepared as previously described (see also Figure 3.1A) [104]. 
Approximately 
1.5 mL of 1002F 
was poured into 
the center of a 
plasma-cleaned 
glass slide (75 × 
25 × 1 mm, 
Corning, 
Corning, NY). 
The photoresist 
was spin-coated 
onto the slides 
by spinning at 
Figure 3.1. Pallet array fabrication.  a) Schematic showing patterning of array 
(step 1), poly(acrylic) acid (PAA) contact printing (step 2), deposition of 
hydrophobic silane layer (step 3), Removal of PAA layer (step 4), and 
polystyrene-copolymer contact-printing (step 5). b) Brightfield image of pallet 
with no coating. c) Brightfield image of pallet contact-printed with 5% AA in 
PS. d) ESEM image of pallet viewed on edge showing polystyrene thickness. 
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500 rpm for 10 s, followed by 2200 rpm for 30 s. Photoresist, coated on glass slides, was 
placed in a 95 C oven (Fisher Scientific, Dubuque, IA) for a 50 min soft bake, removed 
and allowed to cool to room temp. Soft baked photoresist was placed on a UV exposure 
system (Oriel, Newport Stratford, Inc., Stratford, CT) and illuminated with 1500 mJ. 
Exposed photoresist was returned to the 95 C oven for a 10 min post-exposure bake 
(PEB), removed and permitted to cool to room temp. PEB-photoresist was placed in a 
photoresist developer (1-methoxy-2-propyl acetate, Sigma-Aldrich, St. Louis, MO) on a 
rotary shaker for 4 min. Developed photoresist was rinsed with 2-propanol (VWR, West 
Chester, PA), blown dry with nitrogen, and placed on a hotplate at 95 C  for 10 min, 
followed by 70 min at 120 C. To add the polystyrene film, room temp photoresist films 
were again placed on the spin coater, coated with 3 mL of the desired polystyrene by 
spinning at 500 rpm for 10 s. Polystyrene-coated photoresist films were then placed in a 
60 C vacuum oven (VWR, West Chester, PA) for at least 48 h to evaporate any 
remaining solvent. 
 
Micropallet Array Fabrication and Contact Printing of Polystyrene and 
Extracellular Matrices (ECMs) 
  Micropallet arrays were fabricated as previously described (see also Figure 
3.1A) [58, 104]. Briefly, a mask outlining numbered micropallets was used to 
photolithographically define a 50 × 50 array of 150 × 150 × 50 m (L x W x H) 
micropallets possessing a 50 µm gap between micropallets. Polyacrylic acid (PAA) 
(Polysciences Inc., Warrington, PA), 25% in aqueous solution (MW:~50,000) diluted to 
8% in DI water, was applied to the upper micropallet surfaces via contact printing [64]. 
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This deposited PAA would serve later as a sacrificial layer to remove the organosilane 
([heptadecafluoro-1,1’, 2, 2’-tetrahydrodecyl] trichlorosilane, Gelest, Morrisville, PA) 
from the top surface of the micropallets. Only arrays possessing ≥90% fully PAA-coated 
micropallets were used in subsequent steps. Approximately 80% of the arrays met this 
criterion. The organosilane was applied by vapor-deposition in a vacuum chamber as 
previously described [58]. Arrays were removed from the chamber, incubated in 
deionized water for 30 min and rinsed with deionized water to remove the sacrificial 
PAA layer. Micropallet surfaces were then contact-printed with the desired polystyrene 
coatings (Table 3.2),again only using arrays possessing ≥90% fully polystyrene-coated 
micropallets in subsequent steps [64]. Again, approximately 80% of the arrays met this 
criterion. Once printed with polystyrene, arrays were placed in a 60 C vacuum oven for 
48 h to remove any remaining solvent. Arrays were sterilized with 75% ethanol and 
allowed 30 min to dry.  
 To contact-print ECMs, 5 L of 1 mg/mL collagen or 3 µL of 1 mg/mL gelatin 
was added to a sterile glass slide and spread with the side edge of a pipette tip to cover a 
1 cm
2
 area. Arrays were then inverted and pressed against the protein-coated slide and 
removed to create a single-layer coating. This procedure was repeated to create a double-
Table 3.2. Optimized parameters for contact printing various copolymers onto 1002F surfaces. 
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layer coating. In experiments to determine the persistence of the gelatin layer contact 
printing, gelatin was labeled with a fluorescent Alexa Fluor®568 (Invitrogen, Carlsbad, 
CA) per manufacturer protocol. Labeled gelatin was printed in two layers onto the 
micropallets, allowed to dry, placed in standard growth conditions and imaged. Cells 
were plated onto the array and images were taken again at 24 and 96 h.  
 Measuring Contact-Printed PAA and Copolymer Thickness  
 Micropallets contact-printed with copolymers were observed using an 
environmental scanning electron microscope (ESEM) (Quanta 200, FEI Company, 
Hillsboro, OR). The ESEM was performed in low vacuum (0.75 Torr) mode and a 
backscattered electron detector was used to acquire images. Contact-printed micropallets 
were also removed from the glass surface and imaged from the side (Figure 3.1D). The 
thickness of the contacted-printed copolymer layer, in addition to the thickness of the 
contact-printed PAA layer, was measured using a profilometer (P6 Stylus Profilometer, 
KLA Tencor, San Jose, CA). Copolymer and PAA thickness were determined by 
measuring micropallet height before and after contact-printing.  
Experiments Studying Cell Adherence and Proliferation 
 Cell chambers were created from poly(dimethylsiloxane) (PDMS) reservoirs (10 
× 10 × 8 mm) glued with uncured PDMS onto the 1002F and copolymer films or 
micropallet arrays. Before use, the cell chambers were sterilized with 75% ethanol and 
allowed to dry 30 min in a tissue culture hood under sterile conditions. Reservoirs were 
rinsed twice with 1 mL of phosphate buffered saline (PBS). Before seeding cells, 500 L 
of media was added and allowed to sit for 10 min. Cells were then loaded into the 
reservoir as 500 L of an 8000 cells/mL suspension added drop wise into the reservoir in 
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a grid-like pattern to spread the cells evenly over the array. Cells were then placed in a 37 
C incubator (5% CO2, ~95% RH) for up to 96 h during the course of the experiment.  
Cell Imaging and Counting  
 Cells grown on films of copolymer, photoresist, or micropallet arrays were 
stained with 1 µg/mL Hoechst 33342 (Sigma, St. Louis, MO) for 10 min in a 37 C 
incubator. Cells were imaged with an epifluorescence microscope (IX81, Olympus, 
Center Valley, PA) using a Coolsnap HQ
2
 charged coupled device camera (Photometrics, 
Tucson, AZ). For cells on films, six independent images were obtained at 4× 
magnification, and cells were counted using ImageJ software (NIH, Bethesda, MD). Cells 
grown on micropallet surfaces were imaged at 10× and the numbers of cells per 
micropallet were counted using a Matlab script (Mathworks, Natick, MA). 
mRNA Analysis  
 Four aliquots of 150,000 cells were placed in 1.5 mL microcentrifuge tubes. 
Tubes were centrifuged at 600 g for 2.5 min and media was then removed, leaving the 
cell pellet. Pellets were rinsed with 1 mL of 1× PBS and centrifuged again. The 
supernatant was removed leaving the cell pellet in 100 L PBS. A 100 L quantity of 2× 
nucleic acid lysis buffer (Applied Biosystems, Carlsbad, CA) was then added to the tube. 
The suspension was mixed and placed in a -20 C freezer. These tubes were denoted as 
Day 0. Additional aliquots of cells were plated on the experimental surfaces as follows. 
Glass slides (75 × 25 × 1 mm) were coated with 1002F photoresist and 5% AA in PS 
films as described above and PDMS reservoirs were applied. Samples were sterilized 
with ethanol and rinsed with PBS, followed by 4 mL of warmed growth media. A cell 
suspension (37,500 cells/mL, 2 mL) was added drop wise to each plate, applied in a grid-
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like pattern. Plates were then placed in a 37 C incubator (5% CO2, ~95% RH). On Days 
3, 5, and 7, cells were collected for analysis. To collect, samples were rinsed with PBS 
and cells were removed with 500 L of trypsin-EDTA (Invitrogen, Carlsbad, CA) 
followed by addition of 500 L of PBS. Samples were then prepared in the same fashion 
as Day 0. Once all trials were complete, samples were submitted to the UNC-CH Animal 
Clinical Chemistry and Gene Expression Laboratories for RNA analysis using TaqMan 
probes on an ABI PRISM 770 Sequence Detection System (Applied Biosystems, 
Carlsbad, CA) using primer probe sequences developed for Pax7 and Utrophin. Pax7 
primers/probe: Forward (AGT ACG GCC AGA CTG CTG TT), Reverse (AAT GCT 
CCC CGA GCT TCA TA), Probe (Fam AC CTG GCC AAA AAC GTG AGC CTC 
TCTamra). Utrophin primers/probe: Forward (CTG ACA GCA GCT CTA CCA CA), 
Reverse (CCT CCA AGC GTC TGA CAG TA), Probe (Fam TG TGG AGG ACG AGC 
ATG CCC TCA TC Tamra). 
PCSC Separation and Pax7 Verification   
A heterogeneous population of cells derived from a muscle biopsy was obtained from the 
earlier stages of the preplate procedure described above, specifically preplate 4. 2000 
cells were seeded onto an array of 2500 micropallets of dimensions 150  150  50 m 
(LWH). Cells were allowed 48 hrs to adhere and micropallets were examined for 
cellular adhesion. Micropallets containing cells with a spindle-like morphology were 
released from their glass substrate using an ACL-1 532 nm frequency-doubled Q-
switched Nd:YAG laser (New Wave Research, Fremont, CA) generating ~7 µJ laser 
pulses with a 5 ns pulse width as previously described with minor modifications [58]. 
The glass slide containing micropallets was placed inverted atop a 15 × 15  4 mm 
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PDMS reservoir affixed to a glass slide containing culture media (described above). The 
laser was focused at the base of the micropallet through a Nikon Eclipse E800 upright 
microscope (Nikon, Melville, NY) using a Nikon 20 extra-long working distance 
objective (Nikon, Melville, NY). The microscope was fully enclosed in a 37C incubated 
environment with humidity and temperature controls provided by an Air-Therm ATX-H 
Controller (World Precision Instruments, Sarasota, FL) and CO2 control provided by a 
ProCO2 Controller (Biospherix, Lacona, NY) (4% CO2, ~75% humidity). After being 
released into the media-filled tissue culture dish, cells were placed in a 37C incubator 
(5% CO2, ~95% RH) and allowed to proliferate for 48 hrs. After this time, cells were 
stained via a modified protocol for the transcription factor and intracellular marker Pax7 
[57, 75]. Briefly, cells were rinsed in PBS and fixed in a 4% paraformaldehyde solution 
in PBS for 10 min.  Cells were permeablized for 15 min with 0.5% Triton X-100™ in 
PBS to permit antibody access to the nucleus. Primary mouse anti-Pax7 antibody (DSHB, 
Iowa City, IA) used at 2µg per mL was incubated on cells for 12 hrs. Secondary anti-
mouse antibody labeled with AlexaFluor®594 (Invitrogen, Carlsbad, CA) was incubated 
at 4µg per mL on cells for 1 hr. Cells were imaged with the previously described 
epifluorescence microscope using DAPI and Texas Red filters (Olympus, Center Valley, 
PA). 
 
Results and Discussion 
Surface Modifications for Growth of PCSCs 
 The 1002F photoresist from which the micropallet arrays were fabricated has 
been shown to be suitable for culturing tumor cell lines [58, 62]. In some instances, the 
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1002F required an additional coating such as collagen or fibronectin for cell attachment 
and growth. When PCSCs were cultured on the arrays, cells initially adhered to the 
1002F surface, but did not proliferate. The addition of an adsorbed ECM to the 
micropallet surfaces also failed to support cell proliferation. The 1002F beneath the ECM 
may have leached a component toxic to the overlying cells or the ECM may not have 
exhibit the same properties as those on the polystyrene surfaces of tissue culture dishes. 
For this reason, a variety of surface coatings designed to mimic either the glass or 
polystyrene culture surfaces on which these cells are traditionally grown were placed 
onto the arrays. Layers of microbeads (22 nm and 500 nm silica glass or 50 nm 
polystyrene) contact-printed on to the array surfaces exhibited a non-uniform coating, 
with cracking of the printed layer and surface-detachment after 4 days. [64]. Since these 
defects were not compatible with light microscopy and may have also permitted leached 
materials from the 1002F to contact the cells, these modifications were not tested further.    
 Polystyrene is a standard and well-accepted surface for cell culture; therefore, 
polystyrene in an organic solvent was contact-printed onto the micropallets [19]. The 
polystyrene layer exhibited a uniform surface coverage, unambiguous transparency, and 
no visible cracking, Figure 3.1B, C.  The coating also remained on the micropallet 
surface for two weeks in culture, the maximum time examined, making the contact-
printing of thin layers of polystyrene a convenient method of modifying micropallet 
surfaces for microscopy applications.  
 Standard TC dishes are the accepted culture vessel for PCSCs, and were therefore 
used as the gold standard for comparison of cell adhesion and proliferation [81, 99]. 
Commercial TC dishes are oxidized, imparting a negative charge to the surface [105, 
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106]. Direct oxidation of the polystyrene-coated micropallet surfaces was not possible 
since the hydrophobic organosilane coating on the intervening glass surface was not 
stable to oxidants. This hydrophobic coating is used to entrap air between the 
micropallets, blocking cell access to the inter-pallet regions. Since these virtual air walls 
are critical to direct cells to the micropallet surfaces, another strategy was required to 
impart a charge to the polystyrene coating. For this reason, the charged monomers acrylic 
acid (negative charge) or 4VP (positive charge), were mixed into the styrene monomer at 
different concentrations during polymer synthesis to form polystyrene copolymers with 
varying charge densities. To determine whether PCSCs could be cultured on these 
polymers, flat films comprised of the copolymers were assessed for PCSC adherence and 
growth over 4 days, Figure 3.2. PCSCs did not efficiently adhere to or proliferate on the 
uncharged polystyrene or the 4VP in polystyrene. Negatively charged copolymers of 
acrylic acid in polystyrene 
(AA in PS) supported 
greater cell adhesion and 
proliferation than any of 
the other synthesized 
surfaces at all time-points. 
Within the first 24 h, the 
negatively charged AA-in-
PS coating showed no 
significant differences for 
any AA concentration 
Figure 3.2. Cell adhesion and proliferation on various thin film 
substrates. PCSCs purified with the preplate technique were 
cultured on TC dishes, neutral PS, various percentages of AA in 
PS, 1002F photoresist (1002F), or 4VP in PS. Cells were stained 
with Hoechst dye, imaged and counted at 4, 24 and 96 hours. 
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when compared to standard TC dishes. However, by 96 h, PCSCs on the 5% AA-in-PS 
surface exhibited equivalent growth properties to that on the TC dish. In contrast, the 
surfaces with 2.5, 10, 15 and 20% AA in PS demonstrated significantly lower rates of 
proliferation as revealed by the lower cell numbers at 96 h. Cells grown on the TC dish 
and 5% AA in PS showed similar morphology, long slender cells, Figure 3.3. Cells 
grown on the bare 1002F were scattered and more rounded in morphology. These data 
demonstrated that PCSCs adhere to and proliferate on the 5% AA in PS copolymer as 
effectively as on the "gold standard" surface of the TC dish, making 5% AA in PS atop 
1002F micropallets an effective growth surface for these primary cells.  
Characterization of Contact-Printed PAA and Copolymer 
 To determine the thickness of the 5% AA-in-PS layer contact printed on to the 
micropallets, ESEM was used to image individual micropallets. The apparent polymer 
thickness was 1-2 µm, Figure 3.1D. Since the exact orientation of the pallet was difficult 
to ascertain, more precise measurements of the layer thickness could not be obtained 
using ESEM. For a more precise measurement, a stylus profilometer was used to measure 
the height of the micropallet above the glass substrate before and after contact printing 
with 5% AA in PS. The same procedure was completed for the contact-printed PAA. The 
Figure 3.3. PCSCs cultured on various surfaces. a) bare 1002F photoresist film, b) photoresist film 
coated with 5% AA in PS and c) TCPS.  Magnified images of PCSCs grown on these surfaces are 
shown in d-f. 
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copolymer thickness was 1.0 m ± 0.3 µm (n=50), while the PAA thickness was 0.63 µm 
± 0.2 µm (n=50). 
ECM Protein Coatings 
 PCSCs are commonly cultured on collagen or gelatin-coated TC flasks [81, 99]. 
For this reason, gelatin was contact-printed onto the surface of the micropallet arrays 
composed of 1002F micropallets with a 5% AA in PS top layer. To determine whether 
the contact-printed gelatin was stable over time, AlexaFluor®568-labeled gelatin was 
utilized and two layers of fluorescent gelatin were contact-printed onto the array. Arrays 
with or without cultured cells were incubated for 4 days under standard tissue culture 
conditions. Images were taken immediately after the adhesion of cells at 4 h and again at 
24 and 96 h. The gelatin fluorescence intensity on the micropallets decreased from 1.00 at 
4 h to 0.90 ± 0.05 at 24 h. The fluorescence intensity then remained unchanged through 
96 h, indicating that the gelatin remained attached to the surface of the pallet for the 
duration of the culture period. Pallets contact-printed with fluorescent gelatin and 
cultured with cells also demonstrated a drop in fluorescence from 1.00 at 4 h to 0.90 ± 
0.11 at 24 h.  The fluorescence intensity was then unchanged through 96 h. In this 
instance the fluorescence of the cell's cytoplasm plus that of the micropallet surface was 
measured since the two fluorescence sources could not be separated. Cells growing on the 
gelatin demonstrated bright red punctate spots suggesting that they were able to take up 
the fluorescent dye. This phenomenon was most likely due to the enzymatic degradation 
of the fluorescent gelatin by the cells and subsequent uptake of the labeled protein [107].  
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 Cells on 5% AA-in-PS-coated micropallets with either a single or double layer of 
contact-printed gelatin did not demonstrate significant enhancement in initial cell 
adhesion or proliferation compared to those on the 5% AA-in-PS-coated micropallet 
alone, Figure 3.4A&B. Similar results were obtained when collagen was contact-printed 
onto micropallets in either single or double layers. These data suggested that the ECM 
coating was not necessary for PCSC adherence and growth on the micropallets containing 
a 5% AA-in-PS surface.   
 
Monitoring Growth and Differentiation of PCSCs on Standard and Optimized 
Surfaces 
 A risk in culturing cells on novel surfaces is the potential to alter cellular 
properties, such as the induction of PCSC differentiation toward terminally differentiated 
multi-nucleated myotubes [55, 108-110]. This process is regulated by the transcription 
Figure 3.4. Adhesion and proliferation of cells on micropallets contact-printed with selected 
proteins. a) Number of PCSCs adhering at 24 hours to micropallet arrays contact-printed with 5% 
AA in PS alone, with 5% AA in PS followed by contact printing with collagen or gelatin (single) or 
with 5% AA in PS gelatin followed by two-sequential, contact printings with collagen or gelatin 
(double).  b) Ratio of the number of PCSCs counted at 96 hours to 24 hours on micropallet arrays 
contact-printed with 5% AA in PS alone or with an additional single or double layer of collagen or 
gelatin. Micropallet arrays for both (a) and (b) consisted of 2500 micropallets of dimensions 150 
µm × 150 µm× 50 µm (L × W × H). 
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factor Pax7, which maintains the stem cell state. Utrophin, a structural protein, is 
indicative of PCSC differentiation [78, 79]. Differentiation patterns of the PCSCs 
cultured on commercial tissue culture dishes versus films composed of the 5% AA in PS 
were assayed for their ability to remain undifferentiated as well as their ability to respond 
to a differentiation signal.  The relative mRNA expression levels of Pax7 and Utrophin 
corresponding to undifferentiated and differentiated states, respectively, were measured 
[56, 78, 79, 97, 111]. Under standard growth conditions, cells cultured on 5% AA in PS 
and TC dishes remain undifferentiated, maintaining relatively high stable mRNA levels 
of Pax7, Figure 3.5A, and low levels of Utrophin, Figure 3.5B [55]. When subjected to 
standard differentiation conditions (addition of horse serum), the rate of differentiation of 
PCSCs was similar on both 5% AA-in-PS surfaces and TC dishes, as shown by a 
decrease in Pax7 mRNA quantity over time, Figure 3.5A, and an increase in Utrophin 
mRNA levels over time, Figure 3.5B [55]. The samples cultured on the TC dishes or the 
5% AA-in-PS surfaces under either the standard growth or differentiation conditions did 
Figure 3.5 mRNA expression levels under standard growth and differentiation conditions. a) Pax7 
mRNA expression in PCSCs grown on TC dishes (squares) or 5% AA in PS-coated films (triangles) 
in either standard growth (solid symbols) or differentiation (open symbols) conditions. b) 
Utrophin mRNA expression in PCSCs grown on TC dishes (squares) or 5% AA in PS (triangles) in 
either standard growth (solid symbols) or differentiation (open symbols) conditions. For both (a) 
and (b) mRNA expression levels are normalized to Day 0. 
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not demonstrate statistically distinct mRNA levels of Pax7 or Utrophin using a one tailed 
student T-test.   
PCSC Separation and Pax7 Verification 
Satellite cells have been demonstrated to grow with a spindle-like morphology in culture 
(characterized by two to three points of attachment) [67, 88]. Satellite cells also express 
the transcription factor and internal marker, Pax7 [57, 75]. A brief separation and 
verification experiment was devised to demonstrate this correlation. Micropallet arrays 
coated with 5% AA in PS were seeded with a heterogeneous mixture of cells from a 
canine muscle biopsy subjected to the preplate procedure [83]. Micropallets containing 
cells with a spindle-like morphology were identified and released from the array onto a 
plasma-treated glass slide, Figure 3.6A.  After 48 hrs in culture, the presence of cells was 
determined with the use of brightfield images and Hoechst staining, Figure 3.6B and C. 
The presence of the transcription factor Pax7 was examined using immunochemistry, 
Figure 3.6D.  From this experiment, it was found that 88% of the collected micropallets 
containing cells possessed Pax7+ cells. Therefore, micropallets containing cells with a 
spindle-like morphology showed the presence of Pax7 following the separation 
Figure 3.6. Separation of spindle-shaped cells for Pax7 demonstration.  a) Brightfield image of 
spindle-shaped cell growing on 5% AA in PS-coated micropallet before release from array. b) 
Brightfield image of 5% AA in PS-coated micropallet with cells 48 hrs after release from array. c) 
Epifluorescence image of cell nuclei from (b) stained with Hoechst dye (blue). d) Epifluorescence 
image of cell nuclei from (b) stained with Pax7 antibody (red). 
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procedure, thus demonstrating that PCSCs can be sorted with confidence based on 
morphology. 
 
Conclusions 
A suitable copolymer surface has been developed for the culture of PCSCs atop 
micropallets.  Our results show that the 5% AA-in-PS copolymer mimicked the ability of 
tissue culture polystyrene in supporting the adhesion and proliferation of the PCSCs. 
Importantly, cells cultured on this surface showed neither induced differentiation under 
standard growth conditions nor a rate of spontaneous differentiation greater than that seen 
with the control TC dish under standard differentiation conditions as indicated by mRNA 
levels of Pax7 and Utrophin. This copolymer material was readily and consistently 
applied to the surface of the micropallets using the described contact printing procedure. 
Experiments using additional contact-printed layers of the ECM proteins collagen and 
gelatin on the 5% AA-in-PS layer showed no increase in either initial PCSC adhesion or 
proliferation rates relative to surfaces without the extracellular matrices. The contact-
printing method developed in this study is readily applicable to screen thick coatings of 
almost any polymer matrix for the growth and well-being of primary cells including stem 
cells. More importantly this should enable, as we have demonstrated, the sorting of 
primary cells cultured on the arrays based on a number of cellular attributes (morphology 
and other spatial properties, growth rate and other temporal behaviors) not accessible by 
current cell separation methods such as preplating and flow cytometry. 
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Chapter 4 
Sorting Primary Canine Satellite Cells with Tri-Partite Micropallet Arrays 
Introduction 
Muscular dystrophy is a family of diseases that are characterized by progressive 
dysfunction in the musculature of diseased individuals. Of all the muscular dystrophies, 
Duchenne muscular dystrophy (DMD) is the most severe form. It affects 1 in 3,500 males 
and is diagnosed in childhood and leads to muscle degeneration in the teens to early 
twenties ending in death in the late teens and early twenties. Dystrophin allows cells to 
transmit forces coming into and leaving muscle cells evenly, lack of dystrophin results in 
uneven force distribution and damages to cell membranes. By this mechanism, muscles 
are repeatedly damaged forcing regeneration of the tissue.  Repetitive rounds of damage, 
necrosis and regeneration lead to widespread muscle atrophy, with fibrosis and fatty 
change as the disease progresses, associated loss of strength and muscle mass.     
Cellular therapies to treat DMD are aimed at restoring the strength and mass of 
the skeletal muscle.  Since the host’s own cells are diseased, cell therapies require 
donated cells, allogenic therapy, or correction of the host cells followed by re-
implantation, autologous therapy.  Both pathways require a population of cells that can 
support regeneration of the skeletal muscles for the lifetime of the patient.  Adult stem 
cells, found in most if not all tissues are the lead candidates as the cell source to develop 
cellular therapies for DMD.   
To test newly developed therapies along with characterizing new and existing 
stem cell populations, animal models are commonly used.  DMD has two models of 
primary importance.  The first is the muscular dystrophy X-linked (mdx) mouse and the 
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second is Golden Retriever muscular dystrophy (GRMD).  The mouse model has been 
extensively employed to understand the molecular pathways and disease progression in 
DMD.  However, the mouse model is not entirely consistent with the human disease 
(Kuhana et al.).  The GRMD model is more consistent with the human disease and is a 
more size relevant model than MDX.  For this reason, we are using cells derived from the 
GRMD model.   
Satellite cells are the stem cell of skeletal muscle and as such are responsible for 
the regenerative capacity of muscle.  They are found on the surface of myofibers in a 
quiescent state until the fiber is damaged, at which time the satellite cell will become 
activated.  Activated cells proliferate and repair damage.  Once the damage is fixed some 
of the proliferating cells can again become quiescent satellite cells.   
Pax7 is a transcription factor that is responsible for maintaining quiescent satellite 
cell populations and allows these cells to again become quiescent. It is considered to be 
the strongest and most reliable marker of adult satellite cells. Pax7 also inhibits the 
differentiation of satellite cells and myoblasts.  Once myoblasts have up-regulated 
another transcription factor, myogenin, Pax7 levels fall, allowing the fusion and terminal 
differentiation of the myoblasts to myotubes.  These transcription factors can be used to 
determine the stem cell state of a given satellite cell. 
Stem cells are often characterized by flow cytometry for markers which act as 
surrogates for stem cell properties.  Stem cells have many other properties beyond surface 
markers that characterize their behavior, characteristics that can’t be used to sort cells 
with a flow cytometer.  Additionally, newly discovered stem cells or animal models in 
the early stages of being characterized may not have the antibody repertoire needed to 
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fully characterize them, as is the case for GRMD model.  Other technologies are needed 
to sort stem cells based on these alternative properties, including but not limited to 
proliferation rate, cell morphology, enzymatic function and mobility.  One technology 
that can characterize cells based on these alternative factors and simultaneously be used 
to sort cells is micropallet array technology [60-63, 112].    
Micropallet arrays allow adherent cells to be cultured on a solid surface, which 
can be modified and adapted to a specific cell type, see Chapter 3.  Cells can be cultured 
in clonal fashion on micropallet arrays, important in deciphering stem cell characteristics 
by eliminating the heterogeneity of multicellular cultures.  Micropallets are made using a 
photolithography technique to cure a photoresist polymer on standard microscope slides 
[60, 63, 112, 113].  Almost any array pattern can be established to achieve a desired 
culture scheme.  The arrays are then treated with a hydrophobic silane which enables the 
formation of virtual air walls between the individual pallets [113].  This forces cells to 
land on the pallet tops and not in between neighboring pallets, Figure 1.1B.  The top 
surface of the micropallets can be treated with a number of polymers and proteins to 
allow for cellular attachment.  Once cultures are established, individual pallets can be 
released with a laser pulse allowing the cells attached to a pallet to be isolated in a less 
traumatic fashion than trypsinization [63, 112].  Released pallets can then be collected for 
analysis or placed in a larger culture environment to expand a clonal colony.    
Culture and isolation of cells on micropallet arrays has several advantages over 
flow cytometry.  Flow cytometry requires cells to be non-adherent to pass through the 
machine requiring the use of trypsin or other means of enzymatic digestion to remove the 
cells from a culture surface.  The cells must then be kept on ice and passed through the 
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flow cytometry apparatus.  Cells can be sorted based on many parameters but not for 
Pax7 expression as it is not a surface protein [74, 97].  Cells can be individually sorted 
into multiwell plates for clonal expansion.  This would then require another trypsinization 
step in order to obtain some cells for staining with a Pax7 antibody to determine colonies 
of interest.  Micropallet arrays require fewer and less traumatic steps in order to obtain 
the desired information. 
Given the versatility of micropallet array technology and its ability to culture 
single adherent cells on a culture surface, it can be used to better characterize the stem 
cell populations derived from muscle.  In order to do this, a cell culture format that can 
allow the clonal culture of cells as well as allow the separation of a given colony into two 
or more sister colonies is needed.  Splitting a clonal colony into multiple sister colonies 
allows cells to be analyzed for different parameters, including assays that may be 
destructive to one of the sister colonies.  A format of 
micropallet array, called tri-partite arrays, has been 
developed to split a clonal colony into two parts, 
Figure 4.1.   Cells are seeded onto an array to obtain 
clonal colonies.  Cells that successfully attach to one of 
the sister pallets can expand numbers and migrate 
across the bridge pallet to the other sister pallet, 
effectively splitting the colony into two separable parts. 
Briefly, satellite cells are seeded onto an array 
that can contain thousands of individual pallets in a 
square centimeter which can be covered by a single 
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Figure 4.1. Tri-partite pallet 
culture scheme. 
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milliliter of culture media.  This can provide thousands of cloning sites in the small 
culture area, much more efficient than limiting dilution or flow cytometry cloning of 
individual cells. Pallets with single adherent cells can be recorded with the aid of an 
automated microscope and custom software scripts. After an expansion period, the 
recorded clones are rescanned to determine which colonies expanded and were able to 
cross the bridge.  Half of the bridge pallet containing the clonal cells can then be released, 
collected for analysis, or cultured.  The remaining half of each colony can also be 
analyzed or further cultured, depending on which format will give the desired 
information. In the case of satellite cells half of a clonal colony would be released for 
culture and the remaining half would be stained for Pax7 expression.  The cells for 
culture and eventual transplantation do not have to be exposed to harsh trypsinization nor 
exposure to antibodies which can alter cell physiology.  Utilization of micropallet array 
technology reduces the amount of stress that cells are put under and reduces the amount 
of resources, plates, media and time, which are required to obtain the necessary 
information to identify colonies of interest.  
 
Materials and Methods 
Micropallet Array Fabrication and Contact Printing of Polystyrene  
Micropallet arrays were fabricated as previously described (see also Figure 1.1A) [58, 
104]. Briefly, a mask outlining numbered micropallets was used to photolithographically 
define a 80 × 80 array of 120 × 120 × 50 m (L x W x H) numbered tripartite 
micropallets possessing a 60 µm gap between micropallets and a 40 µm  gap between 
sister pallets that contains the bridge element, Figure 4.2.  Photoresist 1002F was used to 
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make the pallets.  Polyacrylic acid (PAA) (Polysciences Inc., Warrington, PA), 25% in 
aqueous solution (MW:~50,000) diluted to 8% in DI water, was applied to the upper 
micropallet surfaces via contact printing [64]. This deposited PAA would serve later as a 
sacrificial layer to prevent the organosilane ([heptadecafluoro-1,1’, 2, 2’-tetrahydrodecyl] 
trichlorosilane, Gelest, Morrisville, PA) from binding to the top surface of the 
micropallets. Only arrays possessing ≥90% fully PAA-coated micropallets were used in 
subsequent steps. Approximately 80% of the arrays met this criterion. The organosilane 
was applied by vapor-deposition in a vacuum chamber as previously described [58]. 
Arrays were removed from the chamber, incubated in deionized water for 30 min and 
rinsed with deionized water to remove the sacrificial PAA layer. Micropallet surfaces 
were then contact-printed with the polystyrene coating optimized for culture of PCSCs, 
5% AA in PS, again only using arrays possessing ≥90% fully polystyrene-coated 
micropallets in subsequent steps [64]. Again, approximately 80% of the arrays met this 
criterion. Once printed with polystyrene, arrays were placed in a 60 C vacuum oven for 
48 h to remove any remaining solvent. Arrays were sterilized with 75% ethanol and 
allowed 30 min to dry. PDMS reservoirs were attached to the slide surface to provide a 
well for culture media.  The PDMS was placed ~2 mm from the edge of the array, on all 
sides. Uncured liquid PDMS was used to glue the reservoir to the array by placing a 
small bead of PDMS around the outer perimeter of the reservoir. 
Cell Isolations and Culture  
PCSCs were isolated from muscle biopsies of the vastus lateralis of a normal dog 
in the GRMD colony at University of North Carolina at Chapel Hill (UNC-CH). Cells 
were isolated from biopsies as previously described with minor modifications [65, 81]. 
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Briefly, biopsy material was finely minced and digested with collagenase in growth 
media, 16.5% FBS in Dulbecco’s Modified Eagle Media (DMEM), for 6-8 h. Material 
was rinsed and digested with 0.05% trypsin for 1 hr with agitation every 15 min. Material 
was the passed through a 100 µm screen followed by a 40 µm screen and plated on 0.1% 
gelatin (Millipore, Billerica, MA) coated tissue-culture-treated polystyrene Petri dishes 
(BD Falcon, Franklin Lakes, NJ). Six successive platings with the preplate procedure 
resulted in enriched populations of PCSCs, with cells from plates 4, 5, or 6 used in the 
current experiments [81, 99]. To confirm the presence of PCSCs, 1000 cells from passage 
two of preplate 5 were fixed and stained with anti-desmin antibodies and counterstained 
with Hoechst dye. Desmin, a marker for PCSC, was detected in 94% of the cells. The 
enriched cell populations were further cultured in uncoated TC dishes in 20% fetal 
bovine serum in Dulbecco’s Modified Eagle Medium (DMEM), with 1% penicillin-
streptomycin, defined as standard growth conditions [55].  
Cells were cultured at a density of 1000 cells per cm
2
 and passed every two or 
three days to prevent overcrowding and spontaneous differentiation.  Cultures were not 
used past passage five to maintain the integrity of the cells.  To seed cells on arrays, cells 
were trypsinized with a trypsin-EDTA solution (SIGMA, St. Louis, MO) for no more 
than five minutes.  Cells were counted with a hemocytometer and diluted down to 3000 
cells per mL of growth media.  One mL of cell suspension was gently pipetted onto the 
array to prevent air wall disruption and immediately placed into a tissue culture 
incubator.  After 18 hrs of adhesion, arrays were rinsed with 1 × PBS to remove any non-
adherent cells.   
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Single cell and bridging colony detection 
After removal of non-adherent cells, growth media containing 1µg/mL Hoechst 
dye 33342 was gently pipetted onto the array and allowed to incubate for 10 minutes to 
permit Hoechst dye to label DNA in cell nuclei.  Arrays were then placed on the 
microscope stage to be scanned.  An Olympus IX 81 (Olympus, Center Valley, PA) with 
an ASI 2000 XY motorized stage was used in conjunction with a custom made Python 
(Python Software Foundation, Wolfeboro Falls, NH) script to scan the arrays.  Individual 
images are taken of each pallet for brightfield and Hoechst images.  A custom Matlab 
(Mathworks, Natick, MA) script was used to identify pallets with only one nucleus, 
identified via intensity of Hoechst staining.  Arrays were then removed from the 
microscope and Hoechst containing media was replaced with normal growth media.  
Cells were allowed to proliferate for an additional 72 hours and then again stained with 
Hoechst dye to label nuclei, rescanned with the microscope and analyzed for single cell 
colonies that proliferated and bridged from one sister pallet to the other.   
Pax7 and myogenin immunocytochemistry 
 Following the second scan, arrays were stained with custom labeled antibodies to 
Pax7 and myogenin transcription factors.  Cells on arrays were fixed with a 4% 
paraformaldehyde solution in 1 × PBS for 10 minutes.  Cells were permeabilized with 
0.5% Triton X-100 in 1 × PBS for 15 minutes to permit antibody entry into the cell 
nuclei.  Antibodies for Pax7 and myogenin (DSHB, Iowa City, IA) were labeled with an 
AlexaFluor™ protein labeling kit (Invitrogen, Carlsbad, CA).  Pax7 was labeled with 
Alexa 568 and myogenin with Alexa 488 per manufacturer’s instructions.  Cells were 
labeled for 4 hours with a 1:50 dilution of the labeled antibodies in a 1 × PBS solution 
61 
 
containing 2% FBS.  Arrays were washed with PBS once for 15 minutes to remove 
excessive antibodies and covered with 1 × PBS with FBS solution containing 2% FBS. 
Arrays were then rescanned on the microscope system to image cells.  
 
Results 
 Arrays with 3200 culture sites were seeded with 3000 cells and scanned at 18 hrs 
to identify clonal colonies.  Of the seeded cells 1222 ± 293 (n=8) cells attached to the 
array.  Of these 1222 cells, 411 ± 57 (33.6%) were single cell colonies, as determined by 
60 µm 
A C B 
Figure 4.2. Proliferation of single cell clones and bridge crossing. Single cell colonies identified at 
18 hrs after seeding.  Proliferation without bridging (A), proliferation with minimal bridging (B), 
proliferation with robust bridging (C). 
Figure 4.3.  Matlab analysis of primary 
canine satellite cell platings on tripartite 
arrays.  Nuclei counts: Initial adhesion 
at18 hrs (A), Proliferation of single cell 
clones at 96 hrs (B), Contamination of 
tripartite arrays at 96hrs (C).  
A B 
C 
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Hoechst staining, Figure 4.3A. Cells were allowed to proliferate across the bridging 
pallet for 72 hours.  There were three outcomes for cells: proliferation without bridging, 
proliferation with minimal bridging, and proliferation with successful bridging, Figure 
4.2 A, B & C respectively.  
 General proliferation was considered to be the ability to undergo one or more cell 
divisions and 166 ± 12 clones (40%) were able to do this, Figure 4.3 B (green).  39 ± 9 
clones (11%) were able to proliferate with three or more cell divisions, Figure 4.3 B 
B 
C 
D 
E 
60 µm 
A 
Figure 4.4.  Pax7 and Myogenin expression in canine satellite cells.  Pax7 expression in a colony 
of cloned cells at 90 hrs after seeding (left) Hoechst labeled nuclei overlayed on brightfield 
image (right). (A).  Hoechst (B and D), Pax7 (C), and Myogenin (E) staining of canine satellite 
cell cultures differentiated for 5 days. Arrows indicate nuclei in myotubes in Pax7  (C) and 
Myogenin (E) cultures.  
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(red).  Contamination was an issue with arrays after 90 hours.  All sites without any cells 
at 18 hrs were identified in the scan.  After cells divided for an additional 72 hours and 
the array rescanned, sites that were previously empty but now contained cells were 
identified, Figure 4.3 C (red). Most of the contamination was around the perimeter of the 
array.   
 Arrays were fixed and stained with the pre-labeled antibodies against Pax7 and 
myogenin. Pax7 was able to successfully label 92% of the nuclei on the array after 
expansion, at 90 hrs of culture.  The original pre-plate isolation for these normal cells, 
“Pedro” in Table 2.2, showed 93% of cells were positive for Pax7, Figure 4.4C.  Only a 
few cells stained positive for myogenin protein on any given array.   
 
Discussion 
 Tri-partite micropallet arrays are a flexible tool that can be used to clone and 
characterize stem cell populations.  The overall size of the array can be modified to 
obtain the desired number of cloning sites that are needed for analysis.  The size of the 
arrays is also adjustable to any needed configuration.  Square pallets with a single 
crossing point were chosen to streamline the use of scanning software with the tripartite 
arrays.  This may not be the ideal geometry configuration to maximize cloning of satellite 
cell.  A half-moon on each side of the bridge may reduce the amount of distance that a 
cell has to randomly walk in order to cross the bridge and create a sister colony. Also the 
size of the arrays could be reduced to further reduce the distance that cells need to 
migrate and may reduce the time cells need to cross the bridge.  
C 
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 The period of 90 hours was chosen because canine satellite cells divide once 
every 24 to 36 hrs.  This allows cells to divide between three and four times and should 
allow a clonal colony to reach 8 (2^3) to 16 (2^4) cells per colony.  Colonies with fewer 
than eight cells may not be crowded enough to fully encourage cells to cross over the 
bridge to the open space of the sister pallet.  However, colonies with more than 16 cells at 
90 hrs, may have been contaminated with other cells after the first scan at 18 hrs.  More 
information is needed as to the range of proliferative capacity and migratory capabilities 
of canine satellite cells on micropallets to determine if these colonies can be successfully 
cloned.  
 Contamination issues are of concern because this is a continuous media 
environment that can permit cells that become detached during media changes or moving 
them back and forth between the microscope and the incubator can compromise the 
validity of the clonal colonies.  There were several “clonal” colonies that had more than 
16 cells in the colony, Figure 4.3B (red).  These could be hyper proliferating stem cells 
that may be of great interest and value to the muscular dystrophy community or they 
might just be contaminated cultures that are not valid.  Also, there is a large amount of 
contamination around the periphery of the array.  These also happen to be the areas on an 
array that are most susceptible to air wall breakdown [113].  Some areas lost air wall 
integrity at the time of seeding allowing cells to fall in between pallets.  Canine satellite 
cells can grow very well on glass slides and can easily contaminate any neighboring 
pallets.  Other areas can suffer air wall breakdown after several hours in the high 
humidity environment of the cell culture environment. Using larger micropallet arrays 
may be able to decrease some of the air wall issues leaving more sites open to cloning.   
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 The density of cells may also be reduced to increase the likelihood that a clonal 
colony is formed and fewer cells on the same number of cloning sites would mean that 
cells have to travel further to contaminate neighboring pallets that have clonal colonies 
growing on them.     
 Tri-partite micropallet arrays can be used to clone primary canine satellite cells 
and can do so without the loss of Pax7 or induction of myogenin transcription factor 
expression.  Further work needs to be done to characterize cell motility, proliferative 
capacity and contamination mechanics on the tripartite arrays, in order to validate this as 
a truly useful single cell cloning and sorting technology. 
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